Genmab A/S
GMAB
Positions held
Your positionsGMAB isn't in your positions.
Add it to see shares, cost, and P&L here.
Bull / bear case
Site-generated summary from fundamentals, news, and score — not investment advice. As of 2026-10-08.
- Genmab A/S operates in the biotechnology sector, which is characterized by rapid innovation and significant growth potential, particularly in oncology treatments.
- Revenue increased by 29% compared to the prior quarter, reaching $1.2 billion.
- Operating margin expanded to 35.2%, indicating improved operational efficiency.
- The biotechnology industry faces intense competition, which can impact pricing and market share for companies like Genmab.
- Earnings growth has declined by 9.4% year-over-year, reflecting potential challenges in profitability.
- The company has a high debt-to-equity ratio of 88.5, which may pose financial risks.
Fundamentals
| Market cap | $22.17B | Enterprise value | $25.29B | Trailing P/E | 28.39 | Forward P/E | 23.64 |
| PEG | 4.64 | Price / book | 3.61 | Beta | 0.65 | Dividend yield | 0.00% |
| Revenue growth | 24.9% | Earnings growth | -9.4% | Gross margin | 93.0% | Operating margin | 35.2% |
| Profit margin | 19.1% | ROE | 14.0% | ROA | 8.8% | Debt / equity | 0.89 |
| Current ratio | 2.46 | Free cash flow | $870.63M | Analyst recommendation | strong_buy | Mean target | $44.13 |
| 52w high | $40.17 | 52w low | $23.62 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $1.2B | $896M | $1.1B | $1.0B | $925M | — |
| Op margin | 35.2% | 25.1% | 23.0% | 44.9% | 38.9% | — |
| Net income | $303M | $53.0M | $31.0M | $401M | $336M | — |
| Gross margin | 92.7% | 92.7% | 92.3% | 94.3% | 93.8% | — |
| Gross profit | $1.1B | $831M | $977M | $964M | $868M | — |
| Operating income | $407M | $225M | $243M | $459M | $360M | — |
- Revenue +29% vs prior quarter ($1.2B vs $896M).
- Gross margin 92.7% (was 92.7% prior quarter).
- Operating margin expanded to 35.2%.
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $3.7B | $3.1B | $2.4B | $2.1B | — |
| Op margin | 33.6% | 32.5% | 32.3% | 43.2% | — |
| Net income | — | $1.1B | $631M | $785M | $450M |
| Gross margin | 93.6% | 95.4% | 98.6% | 100.0% | — |
| Gross profit | $3.5B | $3.0B | $2.4B | $2.1B | — |
| Operating income | $1.3B | $1.0B | $772M | $902M | — |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-07 · Genmab (CPSE:GMAB) Posts Two Strong Trial Readouts, Is The Valuation Now Too Hard To Ignore?
2026-10-07 · AbbVie (ABBV) Cut Frontline DLBCL Progression Or Death Risk By 51%
2026-10-06 · AbbVie Stocks Edge Higher as Lymphoma Trial Cuts Progression Risk 51%
2026-10-06 · European shares rise as retreating bond yields and oil prices boost risk appetite
2026-10-06 · AbbVie's Epkinly Could Be Preferred Frontline DLBCL Agent, UBS Says
2026-10-06 · Genmab’s Lymphoma Bet Delivers a 51% Knockout
2026-10-06 · Dual-acting drug from AbbVie, Genmab scores in frontline lymphoma trial
2026-10-06 · AbbVie's Epcoritamab Combo Shows PFS Benefit in Frontline DLBCL
2026-10-06 · Genmab Shares Climb After Positive Study Results for Blood-Cancer Drug
2026-10-06 · Genmab jumps as its lymphoma drug combo with AbbVie cuts progression, death risk
2026-10-06 · Strength Seen in Genmab (GMAB): Can Its 10.7% Jump Turn into More Strength?
Price (daily)
Full chart · RSI · MACD · patterns